Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

NRG1 Gene Fusions Are Recurrent, Clinically Actionable Gene Rearrangements in KRAS Wild-Type Pancreatic Ductal Adenocarcinoma

8 May 2019

Abstract excerpt

Abstract Purpose: Gene fusions involving neuregulin 1 (NRG1) have been noted in multiple cancer types and have potential therapeutic implications. Although varying results have been reported in other cancer types, the efficacy of the HER-family kinase inhibitor afatinib in the treatment of NRG1 fusion–positive pancreatic ductal adenocarcinoma is not fully understood. Experimental Design: Forty-seven patients with...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Gastrointestinal Tumor Research and Treatment
Share to Neuroendocrine Tumor Research Advances
Share to Pancreatic and Hepatic Oncology Research

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 31068372
DOI: 10.1158/1078-0432.ccr-19-0191

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 3 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

NRG1 Gene Fusions Are Recurrent, Clinically Actionable Gene Rearrangements in KRAS Wild-Type Pancreatic Ductal AdenocarcinomaPMID 31068372Read ↗

NRG1 Fusions in KRAS Wild-Type Pancreatic CancerSemantic proximity Read ↗

Fusion genes in pancreatic tumorsSemantic proximity Read ↗

Successful targeting of the NRG1 fusion reveals durable response to afatinib in lung adenocarcinoma: a case reportSemantic proximity Read ↗

Expert Consensus on the Diagnosis and Treatment of NRG1/2 Gene Fusion Solid TumorsSemantic proximity Read ↗

RNA Sequencing Identifies Novel NRG1 Fusions in Solid Tumors that Lack Co-Occurring Oncogenic DriversSemantic proximity Read ↗

Identification of Targetable Gene Fusions and Structural Rearrangements to Foster Precision Medicine inKRASWild-Type Pancreatic CancerSemantic proximity Read ↗

Detection of NRG1 Gene Fusions in Solid TumorsSemantic proximity Read ↗

Therapeutic Potential of Afatinib in NRG1 Fusion-Driven Solid Tumors: A Case Series.Semantic proximity Read ↗

Characterizing the molecular and clinical implications of NRG1 fusions in NSCLC through integrated RNA and DNA sequencing analysis.Semantic proximity Read ↗

An Oncogenic ALK Fusion and an RRAS Mutation in KRAS Mutation-Negative Pancreatic Ductal Adenocarcinoma.Semantic proximity Read ↗

Integrative analysis of KRAS wildtype metastatic pancreatic ductal adenocarcinoma reveals mutation and expression-based similarities to cholangiocarcinoma.Semantic proximity Read ↗

NRG1 Gene Fusions—What Promise Remains Behind These Rare Genetic Alterations? A Comprehensive Review of Biology, Diagnostic Approaches, and Clinical ImplicationsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.